Will you extrapolate the results of ASTER70s showing no benefit of adjuvant chemotherapy in high Genomic Grade Index, elderly patients with early stage ER+ breast CA, to those with high OncoType > 25?  

Are there sufficient similarities or differences in the two assays to permit extrapolation?  Will these results change your practice?